Account
Watchlists
Bookmarks
Pricing
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Sudeep Pharma Limited is a technology-focused manufacturer of excipients and specialty ingredients for the global pharmaceutical, food, and nutrition sectors. With a strong international presence spanning approximately 100 countries, the company operates three manufacturing plants in Gujarat, India, and a recently acquired facility in Ireland, highlighting its commitment to expanding its global manufacturing footprint and serving a diverse customer base including major multinational corporations.
Nov 21, 2025
Nov 25, 2025
Nov 28, 2025
Mainboard
Closed
895 Cr
95 Cr
800 Cr
₹563 - ₹593
25
Our Company proposes to utilise the Net Proceeds from the Fresh Issue towards funding the following objects:
Capital expenditure towards procurement of machinery for our production line located at Nandesari Facility I, with an estimated amount of ₹75.81 Crores.
Funding general corporate purposes, which will not exceed 25% of the Gross Proceeds from the Fresh Issue.
12.93
138.69
27.88%
39.7%
27.88%
—
27.63%
39.7%
12.93
Market leadership with a diversified portfolio of over 100 products in the high-barrier pharmaceutical and nutrition ingredients industry.
Distinguished global customer base including over 40 blue-chip multinational companies and long-standing relationships with key clients like Pfizer and Merck.
Well-equipped and regulatory compliant manufacturing facilities with numerous global accreditations, including USFDA approval.
Strong research and development capabilities focused on proprietary technologies like encapsulation and granulation, driving product innovation.
Significant revenue concentration from a limited number of customers, posing a risk if key clients are lost.
Manufacturing operations are geographically concentrated, with three of four facilities located in Vadodara, Gujarat, increasing regional risks.
Integration risks associated with the recent NSS acquisition and potential future M&A activities, which could impact operations.
Recent negative cash flow from operating activities indicates potential challenges in managing working capital requirements.
Diversification into high-growth sectors such as precursor cathode active materials (pCAM) for the EV battery market.
Leverage USFDA and other global approvals to expand market share in highly regulated markets like the United States and Europe.
Capitalize on government-led public health initiatives for large-scale food fortification in India and other developing nations.
Growing global demand for specialty nutritional ingredients, functional foods, and pharmaceutical excipients, especially in the Asia-Pacific region.
Intense competition in the pharmaceutical and specialty ingredients industry, which experiences rapid technological advancements.
High dependence on export sales (over 58% of revenue), making the business vulnerable to global trade policies, tariffs, and geopolitical instability.
Stringent regulatory oversight and periodic inspections by authorities like the USFDA; any non-compliance could lead to severe penalties.
Evolving environmental, health, and safety laws in India and globally could impose new compliance requirements and increase operational costs.